Ghia P, Barr PM, Allan JN, et al. Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study. J Clin ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Direct immunofluorescence (DIF) microscopy showed a 15.5% positivity rate in pediatric patients and changed the clinical ...

An analysis of key drug trials for psoriatic arthritis shows geographic disparities and racial gaps; most participants have ...